Cargando…

Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases

OBJECTIVES: The purpose of this study was to evaluate the prognostic relevance of temporal muscle thickness (TMT) in melanoma patients with newly diagnosed brain metastases. METHODS: TMT was retrospectively assessed in 146 melanoma patients with newly diagnosed brain metastases on cranial magnetic r...

Descripción completa

Detalles Bibliográficos
Autores principales: Furtner, Julia, Berghoff, Anna S., Schöpf, Veronika, Reumann, Robert, Pascher, Benjamin, Woitek, Ramona, Asenbaum, Ulrika, Pelster, Sebastian, Leitner, Johannes, Widhalm, Georg, Gatterbauer, Brigitte, Dieckmann, Karin, Höller, Christoph, Prayer, Daniela, Preusser, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182383/
https://www.ncbi.nlm.nih.gov/pubmed/30008154
http://dx.doi.org/10.1007/s11060-018-2948-8
Descripción
Sumario:OBJECTIVES: The purpose of this study was to evaluate the prognostic relevance of temporal muscle thickness (TMT) in melanoma patients with newly diagnosed brain metastases. METHODS: TMT was retrospectively assessed in 146 melanoma patients with newly diagnosed brain metastases on cranial magnetic resonance images. Chart review was used to retrieve clinical parameters, including disease-specific graded prognostic assessment (DS-GPA) and survival times. RESULTS: Patients with a TMT > median showed a statistically significant increase in survival time (13 months) compared to patients with a TMT < median (5 months; p < 0.001; log rank test). A Cox regression model revealed that the risk of death was increased by 27.9% with every millimeter reduction in TMT. In the multivariate analysis, TMT (HR 0.724; 95% 0.642–0.816; < 0.001) and DS-GPA (HR 1.214; 95% CI 1.023–1.439; p = 0.026) showed a statistically significant correlation with overall survival. CONCLUSION: TMT is an independent predictor of survival in melanoma patients with brain metastases. This parameter may aid in patient selection for clinical trials or to the choice of different treatment options based on the determination of frail patient populations.